Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study
Open Access
- 18 December 2020
- journal article
- research article
- Published by Springer Nature in The Patient - Patient-Centered Outcomes Research
- Vol. 14 (5) , 533-543
Abstract
Background Non-alcoholic steatohepatitis (NASH) is a progressive form of non-alcoholic fatty liver disease characterized by excessive liver fat accumulation, inflammation, cell injury, and fibrosis. It is viewed as largely asymptomatic in its earlier (non-cirrhotic) stages, and information on the patient-perceived impact of NASH is scarce. Objective This study aimed to develop a NASH-specific patient-reported outcome (PRO) measure (NASH-CHECK) for use as a trial endpoint, using methods compliant with regulatory expectations. Methods A NASH conceptual model was developed based on the literature and clinical/patient expert review. The model guided concept elicitation (CE) interviews in patients with non-cirrhotic NASH recruited via a US tertiary care center. NASH-CHECK content was generated via thematic analysis of CE data and review by clinical/patient experts. Cognitive debriefing (CD) interviews with US patients evaluated content validity. Results The literature review confirmed that NASH impacts on functioning and health-related quality of life (HRQoL). Overall, 23 CE and 20 CD interviews were conducted. Key symptoms reported in CE interviews included pain in the upper-right abdomen (n = 14), fatigue (n = 18), poor sleep quality (n = 12), impaired memory (n = 13), and reduced focus (n = 11); key HRQoL impacts included impaired physical functioning, reduced ability to conduct daily living tasks, reduced quality of relationships, low mood, anxiety, and self-consciousness. The 52-item first-draft NASH-CHECK was reduced to 31 items based on patient feedback on item relevance, acceptability, and comprehension. Conclusions The interviews revealed key symptoms and broad HRQoL impacts of NASH. As a disease-specific PRO measure assessing symptoms and HRQoL, the NASH-CHECK is relevant, comprehensive, and acceptable to patients and clinicians.Keywords
Funding Information
- Novartis Pharma AG
This publication has 37 references indexed in Scilit:
- Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trialHepatology, 2011
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisNew England Journal of Medicine, 2010
- Patient reported outcomes: looking beyond the label claimHealth and Quality of Life Outcomes, 2010
- Quality of life in adults with nonalcoholic fatty liver diseaseHepatology, 2009
- Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitisAlimentary Pharmacology & Therapeutics, 2008
- How Many Interviews Are Enough?Field Methods, 2006
- Using thematic analysis in psychologyQualitative Research in Psychology, 2006
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factorsHepatology, 1990